Welcome

Approximately every second, someone in the world needs a blood transfusion. These transfusions are often needed for trauma victims, cardiac, urologic, orthopedic and vascular surgeries, organ transplants, and patients receiving

treatment for cancer and diseases such as sickle cell and thalassemia. Through volunteer donors, blood can be made available to these patients when they need it most.

In the United States alone, approximately 15 million units of whole blood and red blood cells are donated each year. Typically, whole blood units are separated into red blood cells, plasma, platelets and cryoprecipitate, which are then transfused as blood components based on patients’ needs. 

Advancements in cell separation technologies, such as leukocyte reduction, have led to progressive improvements in the processing of blood and blood components.  Leukoreduction has been shown to be beneficial in reducing some adverse clinical outcomes including:

• Reducing immunization to leukocyte antigens that may complicate care of patients undergoing transplantation or chronic transfusion therapy.
• Reduced transmission of some leukocyte-borne viruses.
• Reduction of recurrent, febrile, non-hemolytic transfusion reaction (FNHTR).

Hemerus is focused on developing innovative, industry-leading technologies to assist in improving the quality and safety of the world’s blood supply, while making blood separation and processing easy, effective, and effortless.